Text Size
2507 studies found for:    "Carcinoma, Non-Small-Cell Lung"

Modify this search | How to Use Search Results

Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Cancel
Rank Status Study
1 Completed FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-Small Cell Lung Cancer
Conditions: Extensive Stage Small Cell Lung Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer;   Recurrent Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Recurrent Non-Small Cell Lung Cancer
Intervention: Drug: FR901228
2 Recruiting Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care
Conditions: Adenocarcinoma of the Lung;   Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Squamous Cell Lung Cancer;   Stage I Colon Cancer;   Stage I Rectal Cancer;   Stage IA Non-small Cell Lung Cancer;   Stage IB Non-small Cell Lung Cancer;   Stage IIA Colon Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIA Rectal Cancer;   Stage IIB Colon Cancer;   Stage IIB Non-small Cell Lung Cancer;   Stage IIB Rectal Cancer;   Stage IIC Colon Cancer;   Stage IIC Rectal Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Rectal Cancer
Interventions: Other: educational intervention;   Other: medical chart review
3 Terminated Pioglitazone Hydrochloride in Treating Patients With Stage IA-IIIA Non-Small Cell Lung Cancer
Conditions: Stage IA Non-small Cell Lung Cancer;   Stage IB Non-small Cell Lung Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIB Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer
Interventions: Drug: pioglitazone hydrochloride;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
4 Active, not recruiting Pemetrexed Disodium and Cisplatin in Treating Patients Undergoing Surgery For Stage I-III Non-Small Cell Lung Cancer
Conditions: Stage IB Non-small Cell Lung Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIB Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Drug: cisplatin;   Drug: pemetrexed disodium;   Other: laboratory biomarker analysis;   Procedure: positron emission tomography;   Radiation: fludeoxyglucose F 18;   Procedure: therapeutic conventional surgery
5 Terminated Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection
Conditions: Stage IA Non-small Cell Lung Cancer;   Stage IB Non-small Cell Lung Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIB Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer
Interventions: Drug: erlotinib hydrochloride;   Procedure: therapeutic endoscopic surgery;   Other: laboratory biomarker analysis
6 Recruiting Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Conditions: Adenocarcinoma of the Lung;   Adenosquamous Cell Lung Cancer;   Large Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIB Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Radiation: hypofractionated radiation therapy;   Other: laboratory biomarker analysis;   Radiation: image-guided radiation therapy;   Drug: carboplatin;   Drug: paclitaxel;   Radiation: stereotactic body radiation therapy
7 Not yet recruiting Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy
Conditions: Stage IA Non-small Cell Lung Cancer;   Stage IB Non-small Cell Lung Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIB Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer
Interventions: Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: mutation analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: Fourier transform ion cyclotron resonance mass spectrometry;   Other: medical chart review;   Other: laboratory biomarker analysis
8 Not yet recruiting Photodynamic Therapy During Surgery in Treating Patients With Non-Small Cell Lung Cancer That Can be Removed by Surgery
Conditions: Recurrent Non-small Cell Lung Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIB Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Drug: HPPH;   Procedure: therapeutic conventional surgery;   Other: photodynamic therapy
9 Completed Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Intervention: Drug: dasatinib
10 Active, not recruiting Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Adenosquamous Cell Lung Cancer;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Non-small Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: cisplatin;   Biological: pegfilgrastim;   Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis;   Genetic: polymorphism analysis;   Other: pharmacogenomic studies;   Genetic: genetic linkage analysis;   Drug: docetaxel
11 Recruiting Azacitidine and MS-275 in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer
Conditions: Recurrent Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: entinostat;   Drug: azacitidine;   Other: pharmacological study
12 Recruiting Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-Small Cell Lung Cancer
Conditions: Recurrent Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Procedure: therapeutic lymphadenectomy;   Radiation: stereotactic body radiation therapy;   Procedure: quality-of-life assessment
13 Active, not recruiting Bevacizumab and Docetaxel in Treating Older Patients With Stage III-IV Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Biological: bevacizumab;   Drug: docetaxel
14 Active, not recruiting Pemetrexed or Erlotinib as Second-Line Therapy in Treating Patients With Advanced Non-Small Cell Lung Cancer
Conditions: Recurrent Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: erlotinib hydrochloride;   Drug: pemetrexed disodium
15 Recruiting Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Conditions: Recurrent Non-small Cell Lung Cancer;   Stage IIB Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Drug: cisplatin;   Drug: etoposide
16 Completed
Has Results 		Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Conditions: Recurrent Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Biological: cixutumumab;   Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
17 Completed GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors
Conditions: Recurrent Non-small Cell Lung Cancer;   Recurrent Prostate Cancer;   Stage III Prostate Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer;   Stage IV Prostate Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: GTI-2040;   Drug: docetaxel;   Other: laboratory biomarker analysis;   Other: pharmacological study
18 Unknown † Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer
Conditions: Non Small Cell Lung Cancer;   Lung Cancer;   Stage IIIA Non Small Cell Lung Cancer;   Stage IIIB Non Small Cell Lung Cancer
Intervention: Drug: S-3304
19 Recruiting Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Recurrent Non-small Cell Lung Cancer;   Stage IA Non-small Cell Lung Cancer;   Stage IB Non-small Cell Lung Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIB Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Drug: acetylsalicylic acid;   Other: laboratory biomarker analysis
20 Terminated EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
Conditions: Advanced Adult Primary Liver Cancer;   Carcinoma of the Appendix;   Fallopian Tube Cancer;   Gastrointestinal Stromal Tumor;   Localized Extrahepatic Bile Duct Cancer;   Localized Gallbladder Cancer;   Localized Gastrointestinal Carcinoid Tumor;   Localized Resectable Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Gastrointestinal Carcinoid Tumor;   Ovarian Sarcoma;   Ovarian Stromal Cancer;   Primary Peritoneal Cavity Cancer;   Recurrent Adult Primary Liver Cancer;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Colon Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Recurrent Gastric Cancer;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Pancreatic Cancer;   Recurrent Rectal Cancer;   Recurrent Small Intestine Cancer;   Recurrent Uterine Sarcoma;   Regional Gastrointestinal Carcinoid Tumor;   Small Intestine Adenocarcinoma;   Small Intestine Leiomyosarcoma;   Small Intestine Lymphoma;   Stage 0 Non-small Cell Lung Cancer;   Stage I Adult Soft Tissue Sarcoma;   Stage I Colon Cancer;   Stage I Gastric Cancer;   Stage I Non-small Cell Lung Cancer;   Stage I Ovarian Epithelial Cancer;   Stage I Ovarian Germ Cell Tumor;   Stage I Pancreatic Cancer;   Stage I Rectal Cancer;   Stage I Uterine Sarcoma;   Stage II Adult Soft Tissue Sarcoma;   Stage II Colon Cancer;   Stage II Gastric Cancer;   Stage II Non-small Cell Lung Cancer;   Stage II Ovarian Epithelial Cancer;   Stage II Ovarian Germ Cell Tumor;   Stage II Pancreatic Cancer;   Stage II Rectal Cancer;   Stage II Uterine Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage III Colon Cancer;   Stage III Gastric Cancer;   Stage III Ovarian Epithelial Cancer;   Stage III Ovarian Germ Cell Tumor;   Stage III Pancreatic Cancer;   Stage III Rectal Cancer;   Stage III Uterine Sarcoma;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Colon Cancer;   Stage IV Gastric Cancer;   Stage IV Non-small Cell Lung Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Pancreatic Cancer;   Stage IV Rectal Cancer;   Stage IV Uterine Sarcoma;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer
Interventions: Drug: EF5;   Drug: motexafin lutetium;   Other: pharmacological study
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years